- Home
- HSHP vs OMER Comparison
HSHP vs OMER Comparison
Compare HSHP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSHP | OMER |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.4M | 844.6M |
| IPO Year | 2022 | 2008 |
Fundamental Metrics
Financial Performance| Metric | HSHP | OMER |
|---|---|---|
| Price | $17.92 | $18.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 442.7K | ★ 1.3M |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | ★ 9.44% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $50.52 | N/A |
| Revenue Next Year | N/A | $73.58 |
| P/E Ratio | $34.01 | ★ $24.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.37 | $4.06 |
| 52 Week High | $19.55 | $21.24 |
Technical Indicators
Market Signals| Indicator | HSHP | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 54.02 |
| Support Level | $14.34 | $18.00 |
| Resistance Level | $18.86 | $19.60 |
| Average True Range (ATR) | 0.54 | 0.84 |
| MACD | -0.23 | -0.16 |
| Stochastic Oscillator | 13.80 | 52.32 |
Price Performance
Historical ComparisonAbout HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is engaged in the operation of dry bulk vessels and focuses on operating a fleet of Newcastlemax dry bulk carriers.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.